ENDPOINTS

PepGen ditches Duchenne programs after mid-stage fail

PepGen is abandoning its exon 51-skipping Duchenne muscular dystrophy candidate after it failed a Phase 2 trial. And it is getting out of the disease altogether as it discards three preclinical programs as well. ...

May 29, 2025 - 12:04
 0
PepGen ditches Duchenne programs after mid-stage fail
PepGen is abandoning its exon 51-skipping Duchenne muscular dystrophy candidate after it failed a Phase 2 trial. And it is getting out of the disease altogether as it discards three preclinical programs as well. ...
Read More

Tags:

Previous Article

Old-school apps with modern perks—get Microsoft Office for your PC for just $25

Next Article

Hold the syrup: Weirdly perfect 'pancakes' on Venus may prove the planet is buck...

Related Posts

#ASCO25: Immatics reports more early-stage data for melanoma cell therapy with pivotal trial underway

#ASCO25: Immatics reports more early-stage data for mel...

May 31, 2025  0

Apnimed posts first set of Phase 3 sleep apnea results, aims for approval filing in 2026

Apnimed posts first set of Phase 3 sleep apnea results,...

May 19, 2025  0

MD Anderson targets $250M for second cancer biotech fund

MD Anderson targets $250M for second cancer biotech fund

May 28, 2025  0